Updated results from the international phase III ALTTO trial (BIG 2–06/Alliance N063D)

AIM: To present the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial. PATIENTS AND METHODS: 8381 patients with stage I-III HER2 positive breast cancer randomized to chemotherapy plus 1-year of: trastuzumab (T), oral lapatinib (L; no longer evaluated), trastuzumab followed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Cancer
Main Authors: Moreno-Aspitia, Alvaro, Holmes, Eileen M., Jackisch, Christian, de Azambuja, Evandro, Boyle, Frances, Hillman, David W., Korde, Larissa, Fumagalli, Debora, Izquierdo, Miguel A., McCullough, Ann E., Wolff, Antonio C., Pritchard, Kathleen I., Untch, Michael, Guillaume, Sébastien, Ewer, Michael S., Shao, Zhimin, Sim, Sung Hoon, Aziz, Zeba, Demetriou, Georgia, Mehta, Ajay O., Andersson, Michael, Toi, Masakazu, Lang, Istvan, Xu, Binghe, Smith, Ian E., Barrios, Carlos H., Baselga, Jose, Gelber, Richard D., Piccart-Gebhart, Martine
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8103014/
https://ncbi.nlm.nih.gov/pubmed/33765513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2021.01.053
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados